Clostebol
Identification
- Name
- Clostebol
- Accession Number
- DB01521
- Description
- Not Available
- Type
- Small Molecule
- Groups
- Experimental, Illicit
- Structure
- Weight
- Average: 322.869
Monoisotopic: 322.169957815 - Chemical Formula
- C19H27ClO2
- Synonyms
- Not Available
Pharmacology
- Indication
- Not Available
- Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More- Pharmacodynamics
- Not Available
- Mechanism of action
- Not Available
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half-life
- Not Available
- Clearance
- Not Available
- Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Unlock Additional DataBeclomethasone dipropionate The risk or severity of edema formation can be increased when Clostebol is combined with Beclomethasone dipropionate. Betamethasone The risk or severity of edema formation can be increased when Clostebol is combined with Betamethasone. Betamethasone phosphate The risk or severity of edema formation can be increased when Clostebol is combined with Betamethasone phosphate. Budesonide The risk or severity of edema formation can be increased when Clostebol is combined with Budesonide. Ciclesonide The risk or severity of edema formation can be increased when Clostebol is combined with Ciclesonide. Clobetasol The risk or severity of edema formation can be increased when Clostebol is combined with Clobetasol. Clobetasol propionate The risk or severity of edema formation can be increased when Clostebol is combined with Clobetasol propionate. Corticotropin The risk or severity of edema formation can be increased when Clostebol is combined with Corticotropin. Cortisone acetate The risk or severity of edema formation can be increased when Clostebol is combined with Cortisone acetate. Deflazacort The risk or severity of edema formation can be increased when Clostebol is combined with Deflazacort. Additional Data Available- Extended DescriptionExtended DescriptionAvailable for Purchase
Extended description of the mechanism of action and particular properties of each drug interaction.
Learn more - SeveritySeverityAvailable for Purchase
A severity rating for each drug interaction, from minor to major.
Learn more - Evidence LevelEvidence LevelAvailable for Purchase
A rating for the strength of the evidence supporting each drug interaction.
Learn more - ActionActionAvailable for Purchase
An effect category for each drug interaction. Know how this interaction affects the subject drug.
Learn more
- Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as androgens and derivatives. These are 3-hydroxylated C19 steroid hormones. They are known to favor the development of masculine characteristics. They also show profound effects on scalp and body hair in humans.
- Kingdom
- Organic compounds
- Super Class
- Lipids and lipid-like molecules
- Class
- Steroids and steroid derivatives
- Sub Class
- Androstane steroids
- Direct Parent
- Androgens and derivatives
- Alternative Parents
- Halogenated steroids / 3-oxo delta-4-steroids / 17-hydroxysteroids / Delta-4-steroids / Cyclohexenones / Alpha-chloroketones / Secondary alcohols / Cyclic alcohols and derivatives / Vinyl chlorides / Chloroalkenes show 3 more
- Substituents
- 17-hydroxysteroid / 3-oxo-delta-4-steroid / 3-oxosteroid / 4-halo-steroid / Alcohol / Aliphatic homopolycyclic compound / Alpha-chloroketone / Alpha-haloketone / Androgen-skeleton / Carbonyl group show 19 more
- Molecular Framework
- Aliphatic homopolycyclic compounds
- External Descriptors
- C19 steroids (androgens) and derivatives (LMST02020019)
Chemical Identifiers
- UNII
- Z7D4G976SH
- CAS number
- 1093-58-9
- InChI Key
- KCZCIYZKSLLNNH-FBPKJDBXSA-N
- InChI
- InChI=1S/C19H27ClO2/c1-18-10-8-15(21)17(20)14(18)4-3-11-12-5-6-16(22)19(12,2)9-7-13(11)18/h11-13,16,22H,3-10H2,1-2H3/t11-,12-,13-,16-,18+,19-/m0/s1
- IUPAC Name
- (1S,2R,10R,11S,14S,15S)-6-chloro-14-hydroxy-2,15-dimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-6-en-5-one
- SMILES
- [H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=C(Cl)C(=O)CC[C@]12C
References
- General References
- Not Available
- External Links
- KEGG Drug
- D07731
- PubChem Compound
- 68947
- PubChem Substance
- 46505505
- ChemSpider
- 62171
- 61686
- ChEBI
- 135372
- ChEMBL
- CHEMBL2106571
- ZINC
- ZINC000004025021
- Wikipedia
- Clostebol
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 189 °C PhysProp - Predicted Properties
Property Value Source Water Solubility 0.0153 mg/mL ALOGPS logP 3.57 ALOGPS logP 3.75 ChemAxon logS -4.3 ALOGPS pKa (Strongest Acidic) 19.31 ChemAxon pKa (Strongest Basic) -0.88 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 2 ChemAxon Hydrogen Donor Count 1 ChemAxon Polar Surface Area 37.3 Å2 ChemAxon Rotatable Bond Count 0 ChemAxon Refractivity 89.22 m3·mol-1 ChemAxon Polarizability 36.16 Å3 ChemAxon Number of Rings 4 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule Yes ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 1.0 Blood Brain Barrier + 0.9754 Caco-2 permeable + 0.828 P-glycoprotein substrate Substrate 0.6367 P-glycoprotein inhibitor I Non-inhibitor 0.6429 P-glycoprotein inhibitor II Non-inhibitor 0.9333 Renal organic cation transporter Non-inhibitor 0.7453 CYP450 2C9 substrate Non-substrate 0.8222 CYP450 2D6 substrate Non-substrate 0.8968 CYP450 3A4 substrate Substrate 0.7867 CYP450 1A2 substrate Non-inhibitor 0.8944 CYP450 2C9 inhibitor Non-inhibitor 0.8654 CYP450 2D6 inhibitor Non-inhibitor 0.8922 CYP450 2C19 inhibitor Non-inhibitor 0.7617 CYP450 3A4 inhibitor Non-inhibitor 0.8467 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.8156 Ames test Non AMES toxic 0.889 Carcinogenicity Non-carcinogens 0.9243 Biodegradation Not ready biodegradable 0.989 Rat acute toxicity 1.7601 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.8594 hERG inhibition (predictor II) Non-inhibitor 0.6749
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Drug created on July 31, 2007 07:10 / Updated on June 12, 2020 10:51